

February 10, 2015

Mr. Guillaume Couillard  
Secretary of the Board  
Patented Medicine Prices Review Board  
Box L40, Standard Life Centre  
333 Laurier Avenue West, Suite 1400  
Ottawa, ON K1P 1C1

**Malcolm N. Ruby**  
Direct 416-862-4314  
Direct Fax 416-863-3614  
malcolm.ruby@gowlings.com  
File No. T999663

Dear Mr. Couillard:

**Re: IN THE MATTER OF the *Patent Act* R.S.C. 1985, c. P-4, as amended  
AND IN THE MATTER of Alexion Pharmaceuticals Inc. (the “Respondent”) and the  
medicine “Soliris”**

---

On behalf of Alexion Pharmaceuticals Inc., we are requesting an extension of time to deliver Alexion’s Response to the Statement of Allegations from February 9, 2015 to March 9, 2015. I understand from counsel for Board Staff that Board Staff does not object to this request. Accordingly, it is our hope that the Board Panel will also be agreeable and, if so, our understanding of the new timetable is as follows:

Delivery by Respondent of its Response:	March 9, 2015
Delivery by Board Staff of their Reply to the Response:	April 10, 2015
Case Management Conference:	On or before April 30, 2015

Since my initial communications with Mr. Morris on the topic of scheduling, I understand that the Attorney General of British Columbia and the Attorneys General of other provinces on whose behalf he speaks, seek Intervener status. If this necessitates further amendment to the schedule, our client will be agreeable to any reasonable adjustment that may be necessary.

Yours very sincerely,

**GOWLING LAFLEUR HENDERSON LLP**

Original signature redacted

Malcolm N. Ruby  
MNR/gm

TOR\_LAW\8626695\1